Letters Safety of GLP-1 drugs

Report all increases in serum amylase in patients starting incretins

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5333 (Published 05 September 2013) Cite this as: BMJ 2013;347:f5333
  1. Zoltán Lengyel, diabetologist1
  1. 1Szent Margit Kórház, Fourth Department of Internal Medicine, 1032, Budapest, Bécsi út 132, Hungary
  1. lengyeldr{at}sztmargit.hu

Cohen recently discussed the potential adverse pancreatic effects of glucagon-like peptide-1 agonists and dipeptidylpeptidase-4 inhibitors.1

Many practising diabetologists have encountered mild asymptomatic increases in amylase activity in patients …

View Full Text

Log in

Log in through your institution


* For online subscription